465 results about "Immune complex" patented technology

An electrochemical immunosensor system with reduced interference, comprising: a first immunosensor that generates an electrochemical signal based on the formation of a sandwich between an immobilized antibody, a target analyte and a labeled antibody, wherein a portion of the signal arises from non-specific binding of the labeled antibody in the region of the first immunosensor, and a second immunosensor that acts as an immuno-reference sensor and generates a signal that is the same as or predictably related to the degree of non-specific binding which occurs in the region of the first immunosensor, and has an immunocomplex between an immobilized antibody and an endogenous or exogenous protein that is in the sample and that is not the target analyte.

Provide herein are fusion polypeptides that comprise a CD47 extracellular domain or a variant thereof that is fused to a Fc polypeptide. The fusion polypeptides are useful for treating an immunological disease or disorder in a subject according to the methods described herein. The fusion polypeptides are capable of suppressing immunoresponsiveness of an immune cell, inhibiting production of proinflammatory cytokines, including inhibiting immune complex-induced production of cytokines.

Provide herein are fusion polypeptides that comprise a CD47 extracellular domain or a variant thereof that is fused to a Fc polypeptide. The fusion polypeptides are useful for treating an immunological disease or disorder in a subject according to the methods described herein. The fusion polypeptides are capable of suppressing immunoresponsiveness of an immune cell, inhibiting production of proinflammatory cytokines, including inhibiting immune complex-induced production of cytokines.

The invention is based in part on the finding that suppressing regulatory T cell function is needed in order to convert passive immunity into active antigen-specific immunity. Generally, the methods of the invention comprise at least the combination of: (1) increasing the amount of immune complexes in the subject, wherein the immune complex comprises a target antigen and a immunoglobulin molecule comprising (i) a variable region specific to the target antigen and (ii) a Fc receptor binding region; and (2) inhibiting regulatory T cell function or decreasing/depleting the regulatory T cell population in the subject.

The present invention discloses a quantum point labeled sandwich immunodetection method and its diagnosis kit. It is a new type sandwich immunodetection method using QDs nano particle as label to make antigen antibody specificity sandwich reaction. It includes the following processes: firstly, directly or indirectly enveloping captured antibody in microwell of polystyrene plate, forming captured antibody-antigen-detection antibody three-layer sandwich luminescent immune complex and fluorescence intensity detection. According to that every QD has narrow and symmetrical fluorescence spectral peak it can select and use quantum point label needle sending different light to simultaneously detect several antigens to be tested in same sample.

The invention provides an indirect competitive quantum dot fluorescence immunological detection method for synchronously detecting multiple small molecular compounds and detection kit, wherein the immunological detection method is a liquid phase immunological detection method which uses an encoded microsphere as a solid phase carrier and a quantum dot as a fluorescent marker and is used for competitive specificity reactions of a small molecular compound antigen. c Firstly, a captured antigen is covalently bound to the surface of the encoded microsphere, an indirect competitive fluorescent immune complex of microsphere-captured antigen-detected antibody-second antibody-quantum dot is formed in a filter film plate reaction hole through capturing the antigen, detecting the antibody and binding the second antibody specificity, and then the indirect competitive fluorescent immune complex flows across a suspension chip or a detection region of a flow analysis system one by one under the restraint of the sheath fluid, recognizes different encoded microspheres and detects the fluorescent intensity (or average fluorescence intensity) of the quantum dot to complete the detection. A plurality of small molecule compounds in the same sample can be synchronously detected, and one or more small molecule compounds in different samples can also be detected. The invention has the advantages of fast speed and high flux.

An adsorbent for removing hepatitis C virus which has the ability to adsorb HCV particles, particularly immune-complex HCV particles, from a patient's body blood safely and with high efficiency and high selectivity for enhancing the efficacy of interferon therapy, an HCV adsorption apparatus including said adsorbent, and a adsorbing method for removing HCV are provided. An adsorbent for removing hepatitis C virus which comprises a compound capable of adsorbing hepatitis C virus as immobilized on a water-insoluble carrier, an adsorption apparatus including said adsorbent, and an adsorbing method for removing HCV.

The invention discloses an application of a Raman encoding microsphere and a method for detecting a tumor marker by utilizing the Raman encoding microsphere, wherein the application of the Raman encoding microsphere refers to the application of the Raman encoding microsphere in tumor marker detection. The method for detecting the tumor marker by utilizing the Raman encoding microsphere comprises the following steps: dispersing the Raman encoding microsphere into a phosphoric acid buffer solution and adding a detection antibody for reaction, thus obtaining a nano probe; then utilizing bovine serum albumin to seal a space bit on the surface of the nano probe, thus obtaining a nano prober marked by Raman encoding; adding serum containing a tumor marker into a solid-phase antibody, reacting and adding the nano prober marked by Raman encoding, thus obtaining an immune complex; and after enriching the immune complex through an additionally added magnetic field, performing SERS (surface enhanced Raman scattering) spectrum detection. The Raman encoding microsphere used in the invention has an ultra-strong SERS effect, and can be used for performing quantitative analysis on a polycomponent ultratrace object, and selecting a large number of molecules with different SERS characteristic oscillation as markers to detect various matters to be detected simultaneously.

The present invention concerns a family of nucleic acids, polypeptides and cloning vectors which direct expression of fusion proteins that can mimic aggregated IgG (AIG) and immune complex function with respect to their interactions with FcγR and which allow for the inclusion and targeting of a second protein domain to cells expressing FcγR. This was accomplished by expressing multiple linear copies of the hinge and CH2 domains (HCH2) of human IgG₁ fused to the framework region of human IgG₁. Convenient restriction sites allow for the facile introduction of additional amino-terminal domains. Methods for treating patients using fusion proteins are also disclosed. The HCH2 polymers described here represent a new strategy in the design of recombinant proteins for the therapeutic targeting of FcγR in autoimmune disorders.

The present invention relates to methods for purifying immunogenic, prophylactically and therapeutically effective complexes of modified heat shock proteins noncovalently associated with antigenic peptides of cancer or infected cells. The claimed methods comprise the constructing of a nucleotide sequence encoding a secretable modified heat shock protein, expressing the sequence in an appropriate host cell, recovering the immunogenic complexes from the cell culture and the cells, and purifying the immunogenic complexes by affinity chromatography. Large amounts of such immunogenic complexes can be obtained by large-scale culturing of host cells containing the genetic sequence. The complexes can be used as a vaccine to elicit specific immune responses against cancer or infected cells, and to treat or prevent cancer or infectious diseases.

A quantitative method for performing an automated diagnostic assay, comprising: incubating a capture reagent with a streptavidin-coated medium to form a solid phase complex; washing the solid phase complex to remove excess capture reagent; incubating the solid phase complex with a serum sample to form an immune complex; washing the immune complex to remove any unbound sample; incubating the immune complex with a conjugate to create an immune-conjugate complex; washing the immune-conjugate complex to remove any unbound conjugate; introducing a substrate capable of generating a quantifiable response; and calibrating the response generated from introducing the substrate.

This invention provides a trivalent immunogenic composition including a soluble portion of a Mycoplasma hyopneumoniae (M. hyo) whole cell preparation; a porcine circovirus type 2 (PCV2) antigen; and a PRRS virus antigen, wherein the soluble portion of the M. hyo preparation is substantially free of both (i) IgG and (ii) immunocomplexes comprised of antigen bound to immunoglobulin.

The invention discloses a gastrin-17 enzymatic chemiluminescence immunoassay kit and belongs to the technical field of chemiluminescence immunoassay analysis. The kit comprises an enzyme label liquid, a gastrin-17 standard, gastrin-17 monoclonal antibody-coated immunomagnetic beads, a sample diluent, a chemiluminescent substrate liquid and a washing liquid. The principle of the gastrin-17 enzymatic chemiluminescence immunoassay kit comprises that a gastrin-17 monoclonal antibody is connected to the surface of a magnetic bead so that a solid phase agent is obtained, and through capture of gastrin-17 in a sample and use of an enzyme-labeled anti-gastrin-17 monoclonal antibody, a solid phase-antibody-antigen-enzyme-labeled antibody sandwiched immune complex is formed. Through combination of a chemiluminescence technology and an immunomagnetic bead technology, the prepared kit has the advantages of high sensitivity, good specificity, wide linearity range and good stability and can satisfy clinical requirements on stomach function detection.

A binding partner, especially an antibody fragment that specifically recognizes an antigen-antibody immune complex between anti-THC and THC (tetrahydrocannabinol), is disclosed. The binding partner facilitates a non-competitive homogenous immunoassay for detection of cannabis use. A test kit comprising the binding partner is also described. Preferably the immunoassay is applied for roadside testing of saliva from suspected drivers.

The invention relates to a magnetic particle chemiluminescence immunoassay method for human thyroglobulin antibodies (TGAb) and belongs to the technical field of immunoassay. TG antigens marked by fluorescein isothiocyanate (FITC) and human IgG antibodies marked by alkaline phosphatase are combined to form an antigen-antibody-second enzyme-labeled antibody sandwich immune complex with a sandwich-like structure. Then, magnetic particles connected with FITC antibodies are added, the antigen-antibody complex is connected to the magnetic particles through specific combination of the FITC antibodies and the FITC and directly deposited in an external magnetic field, and the complex formed by immune reaction can be separated from the other non-combined substances without centrifuging. A kit combines chemiluminescence with the magnetic particles to provide a reaction system close to a homogeneous phase. Compared with the prior art, the kit has the advantages of higher sensitivity, wide linear range, quickness and the like; the cost of a product is greatly reduced; and the kit has a broad application prospect on the aspects of clinical examination and the like.

The invention provides an immunoassay based on a carbon nanomaterial (carbon spot), comprising the following steps of: step A, preparing a carbon spot, and marking an immunoreagent antigen or antibody on a surface of the carbon spot so that the carbon spot becomes an immunoreagent-marked carbon spot; step B, mixing the immunoreagent-marked carbon spot, a sample to be tested and a solid phase substance coated by the immunoreagent antigen or antibody to complete immunoreactions, thus forming an immune complex, and separating the immune complex from a free immunoreagent; and step C, adding an oxidant to the immune complex for chemiluminescence detection, and/or directly enabling the immune complex to be subjected to fluorescence detection. According the immunoassay based on the carbon nanomaterial, the chemiluminescence detection and the fluorescence detection can be performed by using the carbon nanomaterial, and the optical stability is good.

A disclosed method for determining gibberellin based on hybridization chain-reaction signal amplification technology is characterized by: fixing gibberellin antibody on carboxylated magnetic beads so as to form a sandwich-type immunization complex by gibberellin antibody on the magnetic beads, gibberellin antibody on colloidal gold and gibberellin when the target gibberellin exists, adding H1 and H2 both rich in G base, exciting a hybridization chain reaction by DNA1 on colloid gold so as to form a DNA long chain rich in G base on the immunization complex and generate chemical luminescence under the effect of a chemiluminescence agent 3,4,5-trimethoxyphenylglyoxal, and determining gibberellin according to chemiluminescence. The method has the characteristics of high sensitivity, high selectivity, low cost, simple operation and the like.